NDA 018225 · Validus Pharms
Bumex
Bumetanide · Oral · Loop Diuretic
NovelLast checked: Nov 20, 2026Latest source record: Jan 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
Feb 28, 1983
Approved uses
2
Original approval plus efficacy supplements
Registered trials
45
9 Phase 3, 9 recruiting
FAERS reports
26,832
20,610 serious, 4,181 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION ) .
What it is approved for
From the label in effect Dec 17, 2025.
INDICATIONS AND USAGE Bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 14, 1985 Supplement 2 · Efficacy
- Feb 28, 1983 Original approval · Type 1 - New Molecular Entity
3 products under this application
- BUMEX · BUMETANIDE 0.5MG · TABLET, ORAL · Prescription · TE AB
- BUMEX · BUMETANIDE 2MG · TABLET, ORAL · Prescription · TE AB
- BUMEX · BUMETANIDE 1MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bumetanide" as an intervention, any sponsor and status, largest first.
- TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart FailurePivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03296813 · 2,973 participants · Start Jul 11, 2018 · Primary completion Jul 29, 2022
Drug: Torsemide; Furosemide · For: Heart Failure
Sites: Alexander City, Alabama; Huntsville, Alabama; Tucson, Arizona · 60 sites in all
- Effects of Fluid Balance Control in Critically Ill PatientsPivotal-lookingCompleted
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT02765009 · 1,411 participants · Start Jun 1, 2016 · Primary completion Jul 31, 2019
Drug: diuretics; albumin · For: Fluid Shifts; Critical Care
Sites: Belfort, France; Dijon, France; Lyon, France · 11 sites in all
- Bumetanide vs. Furosemide in CirrhosisPivotal-lookingRecruiting
Stacy JohnsonAcademic, hospital or other
NCT06941415 · 500 participants (planned) · Start Jun 3, 2026 · Primary completion Mar 1, 2029
Drug: Bumetanide; Furosemide · For: Cirrhosis
Sites: Salt Lake City, Utah
- Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart FailurePivotal-lookingCompleted
Yale UniversityAcademic, hospital or other
NCT02546583 · 458 participants · Start Aug 31, 2015 · Primary completion Jan 23, 2020
Drug: Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide); IV Chlorothiazide · For: Heart Failure
Sites: New Haven, Connecticut
- Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum DisorderPivotal-lookingTerminated
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT03715166 · 211 participants · Start Sep 24, 2018 · Primary completion Sep 13, 2021
Drug: Bumetanide Oral Solution; Placebo · For: Autism Spectrum Disorder (ASD)
Sites: Curitiba, Brazil; Fortaleza, Brazil; Passo Fundo, Brazil · 45 sites in all
- Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.Pivotal-lookingTerminated
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT03715153 · 211 participants · Start Oct 4, 2018 · Primary completion Oct 26, 2021
Drug: BUMETANIDE (S95008) for week 0 - 26; PLACEBO for week 0 - 26 and 1 more · For: Autism Spectrum Disorder (ASD)
Sites: Staten Island, New York; Liverpool, Australia; Parkville, Australia · 50 sites in all
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "Pivotal-lookingStatus unknown
Instituto Nacional de Cardiologia Ignacio ChavezAcademic, hospital or other
NCT05580510 · 160 participants (planned) · Start Feb 6, 2023 · Primary completion Jul 28, 2023
Drug: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID; Empagliflozin 10 MG OD · For: Congenital Heart Disease; Heart Failure; Heart Failure With Reduced Ejection Fraction
Sites: Mexico City, Mexico
- A Study of Bumetanide for the Treatment of Autism Spectrum DisordersPivotal-lookingCompleted
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT03156153 · 120 participants · Start May 24, 2017 · Primary completion Jul 8, 2019
Drug: Bumetanide; Placebo · For: Autism Spectrum Disorder
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea2,720
- fatigue1,780
- death1,731
- acute kidney injury1,711
- diarrhoea1,628
- nausea1,585
- dizziness1,330
- headache1,301
- pneumonia1,152
- renal failure1,142
- asthenia1,101
- hypotension1,081
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 298 |
| 2005 | 377 |
| 2006 | 366 |
| 2007 | 315 |
| 2008 | 334 |
| 2009 | 411 |
| 2010 | 550 |
| 2011 | 677 |
| 2012 | 719 |
| 2013 | 749 |
| 2014 | 992 |
| 2015 | 1,302 |
| 2016 | 1,653 |
| 2017 | 1,658 |
| 2018 | 1,859 |
| 2019 | 1,944 |
| 2020 | 1,960 |
| 2021 | 1,443 |
| 2022 | 1,357 |
| 2023 | 1,728 |
| 2024 | 2,157 |
| 2025 | 2,268 |
| 2026 | 1,714 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Siafis S, Çray O, Wu H, et al. · Mol Autism 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Anti-seizure medications for neonates with seizures.
Abiramalatha T, Thanigainathan S, Ramaswamy VV, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Clarifications regarding bumetanide for neonatal seizures.
Staley KJ · Epilepsia 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future.
Persico AM, Asta L, Chehbani F, et al. · Prog Neuropsychopharmacol Biol Psychiatry 2025 · Systematic Review, Research Support, N.I.H., Extramural
- Bumetanide: potent new "loop" diuretic.
Asbury MJ, Gatenby PB, O'Sullivan S, et al. · Br Med J 1972 · Clinical Trial, Comparative Study
- Crossover randomized controlled trial of bumetanide to rescue an attack of exercise induced hand weakness in hypokalaemic periodic paralysis.
Scalco RS, Morrow JM, Manole A, et al. · Neuromuscul Disord 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Validus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.